TCMD Tactile Systems Technology Inc.

Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema

Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema

Next-Generation Platform Now Available for Both Upper and Lower Extremity Conditions

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl’s expanded availability to include lower extremity conditions (“phlebolymphedema”) follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema.

“On the heels of Nimbl’s launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 million Americans with chronic swelling in the lower extremities,” said Sheri Dodd, Chief Executive Officer at Tactile Medical. “These patients require effective, convenient therapies to help manage their symptoms. With Nimbl, they now have access to a solution which embodies patient-focused innovation and reflects our commitment to serving patients and improving their care experience.”

Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company’s current generation PCD. The lower extremity garment uses 94% less hosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth® connectivity, providing patients a way to track their treatments and symptom progress with the Company’s free Kylee™ digital application.

“Nimbl for lower extremity lymphedema is intentionally designed as a user-friendly, patient-centric treatment option that is comfortable, clinically effective, and optimized for increased adherence,” said Tony Gasparis, MD, Chief Medical Officer at Tactile Medical. “Its physical dimensions and significant reduction in hose length afford patients the ability to more easily transport Nimbl around the home, or take it with them when traveling, providing an improved all around patient experience.”

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:

Sam Bentzinger

Gilmartin Group



EN
04/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tactile Systems Technology Inc.

 PRESS RELEASE

Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial ...

Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EB...

 PRESS RELEASE

Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial...

Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025 MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the ...

 PRESS RELEASE

Tactile Medical to Present at the Oppenheimer 35th Annual Healthcare M...

Tactile Medical to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time....

Tactile Systems Technology Inc: 3 directors

Three Directors at Tactile Systems Technology Inc sold after exercising options/sold 36,872 shares at between 14.181USD and 14.511USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...

 PRESS RELEASE

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year ...

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch